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To establish the impact of adult strabismus surgery on clinical and psychosocial well-being 2 
and determine who experiences the greatest benefit from surgery and how one could 3 
intervene to improve quality of life post-surgery. 4 
Methods 5 
A longitudinal study, with measurements taken pre-surgery and at 3 and 6 months post-6 
surgery. All participants completed the AS-20 a disease specific quality of life scale, along 7 
with measures of mood, strabismus and appearance-related beliefs and cognitions and 8 
perceived social support. Participants also underwent a full orthoptic assessment at their 9 
preoperative visit and again 3 months postoperatively. Clinical outcomes of surgery were 10 
classified as success, partial success or failure, using the largest angle of deviation, diplopia 11 
and requirement for further therapy. 12 
Results 13 
210 participants took part in the study. Strabismus surgery led to statistically significant 14 
improvements in psychosocial and functional quality of life. Those whose surgery was 15 
deemed a partial success did however experience a deterioration in quality of life. A 16 
combination of clinical variables, high expectations, and negative beliefs about the illness 17 
and appearance pre-surgery were significant predictors of change in quality of life from pre- 18 
to post-surgery.  19 
Conclusions 20 
Strabismus surgery leads to significant improvements in quality of life up to 6 months 21 
postoperatively. There are however a group of patients who do not experience these 22 
4 
benefits. A series of clinical and psychosocial factors have now been identified, which will 23 
enable clinicians to identify patients who may be vulnerable to poorer outcomes post-24 
surgery and allow for the development of interventions to improve quality of life after 25 
surgery.  26 
5 
INTRODUCTION 27 
Strabismus can have debilitating effects on patient’s self-esteem, quality of life and mood 28 
(1). Surgery to realign the eyes is associated with eliminating diplopia, expanding the visual 29 
field and reducing torticollis, as well as overall improvements in quality of life, patient 30 
satisfaction and confidence (2-7). However, this is not the case for everyone. Whilst 95% of 31 
patients achieve clinical success 6 weeks following surgery, only 60% of patients experience 32 
a meaningful improvement in quality of life (8). This suggests that other factors may act as 33 
cofounders to successful improvements in quality of life. Cross-sectional studies suggest 34 
that depression (1;9), beliefs the patient holds about their appearance, strabismus and its 35 
treatment (1), and the expectations patients have about post-surgical outcomes (10) are all 36 
factors associated with quality of life in this population, as opposed to clinical variables. 37 
There has however, been no exploration of how these factors may impact upon surgical 38 
success, or who experiences the optimal quality of life post-surgery.  39 
The studies so far conducted are often flawed by small samples, retrospective designs or 40 
short follow-ups. Hence, larger studies with longer follow-up assessments are needed 41 
(2;11). This study therefore aims to assess how strabismus surgery impacts upon quality of 42 
life and mood in a larger population over a 6 month follow-up period. In order to 43 
understand who may benefit most from surgery and what factors could be targeted in an 44 
intervention to improve the impact of strabismus surgery on quality of life, this study will 45 
also identify the characteristics of patients who experience the greatest improvements in 46 
quality of life. 47 
MATERIALS AND METHODS 48 
Participants 49 
6 
This study presents the follow-up of participants who took part in a previous study (1). 50 
Between November 2010 and April 2012 consecutive adult strabismus patients listed for 51 
surgery at Moorfields Eye Hospital NHS Foundation Trust, London were prospectively 52 
identified. Patients were consented either on the day of being added to the waiting list or at 53 
their pre-operative assessment. Patients were excluded if they had significant co-54 
morbidities, other facial or ocular abnormalities, or identifiable psychosis, dementia, or 55 
other cognitive impairment. Approval was obtained from the North London Research Ethics 56 
Committee. 57 
Measures 58 
All self-report questionnaires were completed prior to surgery and again 3 and 6 months 59 
post-surgery. 60 
Demographic and clinical 61 
Data were collected on age, gender, ethnicity, previous ocular and treatment history at 62 
baseline. All participants underwent a full orthoptic assessment at their preoperative visit 63 
and again at 2 weeks and 3 months postoperatively. Examination included the assessment 64 
of the direction and size of deviation at near (1/3m) and distance (6m) using the alternate 65 
prism cover test (PCAT) and assessment of binocular functions. For multiplanar deviations, 66 
the largest angles, targeted for surgical correction, be that at near or distance, were 67 
recorded for analysis. Diplopia/visual confusion when present was categorised into two 68 
groups based on the position of gaze in which it was present. Diplopia experienced in either 69 
primary position (straight ahead) and or downgaze (reading position), or diplopia 70 
experienced in another tertiary gaze position during ocular motility assessment. Self-71 
7 
reported levels of pain, swelling, scaring and redness, as a result of surgery, were recorded 72 
on a 10-point Likert scale from 0 (no experience) to 10 (severe).  73 
Classification of 3 month postoperative outcome 74 
Three categories were defined: success, partial success or failure based on the surgical 75 
outcome 3 months following strabismus surgery. For success, all of the following categories 76 
had to be met (i) the largest angle of deviation for esotropia, exotropia or hypertropia <12 77 
prism dioptres (PD) and hypotropia <20PD (12) (ii) diplopia/visual confusion either absent or 78 
rarely appreciated in primary position and reading (iii) no requirement for prism or 79 
bangerter foil therapy. For partial success at least one of the above categories should not be 80 
met and failure none of the above criteria met. 81 
Primary outcome measure 82 
The AS-20(13) is a validated, strabismus-specific quality of life instrument. The measure 83 
consists of two subscales; functional and psychosocial quality of life. Scores range from 0 to 84 
100, with higher scores indicating better quality of life. Successful surgery has been defined 85 
as an increase in the psychosocial subscale of 17.7 points and 19.5 points for the function 86 
subscale, these are 95% limits of agreement (LOA) (14). 87 
Psychosocial measures 88 
Participants also completed a series of psychosocial measures taken from the framework of 89 
adjustment to strabismus (Figure 1) (1). Where possible existing validated measures were 90 
used. A full description of the measures employed can be found elsewhere.1 In addition to 91 
these measures the following questionnaires were also completed. 92 
Expectations of, and reasons for seeking surgery 93 
8 
Patients’ reasons for seeking surgery and their expectations about the benefits of surgery 94 
were measured pre-operatively using the Reasons for Strabismus Surgery Questionnaire 95 
(RSSQ) and Expectations of Strabismus Surgery Questionnaire (ESSQ) (10). Each consists of 3 96 
subscales (i) intimacy and appearance-related issues, (ii) social relationships, (iii) visual 97 
functioning. Total subscale scores range from 1-5 for subscales i and ii, and 1-7 for subscale 98 
iii. Higher scores indicate stronger reasons for seeking surgery or higher expectations about 99 
the outcome of surgery.  100 
Satisfaction  101 
Participants were asked if they regretted having surgery, with responses on a 4-point Likert 102 
scale from 1 (yes definitely) to 4 (not at all). Participants also reported on a 4 point Likert 103 
scale from 1 (no hesitation at all) to 4 (certainly not) whether they would go through the 104 
surgery again.  105 
Power calculation 106 
The sample size was powered to look at differences in quality of life overtime. As data were 107 
hierarchically structured multi-level modelling was performed. This requires a sample size of 108 
at least 60, when there are fewer than 5 parameters to be estimated (15). However, in 109 
order to perform a hierarchical regression with the independent variables (IV) outlined in 110 
Figure 1, with an effect size of 0.15 and α=0.05, GPower 3.1.6 indicated a sample size of 217. 111 
Statistical methods 112 
Little’s Missing Completely at Random (MCAR) test indicated no systematic differences 113 
between the observed and missing values (p>0.05). Ten scale-level imputation iterations 114 
were used to eliminate bias. All analyses, except for the multilevel models, were performed 115 
9 
on each of these 10 datasets and then pooled for multiple imputation to give a final 116 
combined result (16). Differences in quality of life between levels of surgical success were 117 
explored using one-way between-groups ANOVA. Multilevel modelling was used to explore 118 
changes over time. As clinical variables were measured at only two time points differences 119 
over time were assessed using either a Wilcoxon Signed Rank test or McNemar's test. 120 
Hierarchical multiple regression were performed to identify the baseline predictors of 121 
changes in quality of life and which changes in the intervening psychological processes 122 
predicted changes in quality of life. The variables were added into the regression based on 123 
the framework (Figure 1). Statistical significance was set at p<0.05.  124 
RESULTS 125 
Participants 126 
Of the 335 patients who consented, 81.49% completed a baseline questionnaire. Of these 127 
210 completed either a 3 (n=41) or 6 month (n=25) follow-up questionnaire, or both 128 
(n=144). Baseline characteristics of the sample can be found in Table 1.  129 
Impact of surgery 130 
Clinical variables 131 
The angle of deviation decreased significantly from baseline (Mean difference (Md)=30, 132 
range 2-90) to 6 months (Md=10, range 0-90; z=-11.81, p<0.001, r=-0.57). There was a 133 
statistically significant reduction in the proportion of participants who experienced diplopia 134 
from prior (58.57%) to 6 months post-surgery (40%; p<0.001). A small proportion (5.85%) 135 
experienced surgery induced diplopia at 3 months, 11 in the primary and downgaze position 136 
and 1 in another gaze. Low levels of pain, swelling, scarring and redness were reported at 137 
10 
both 3 and 6 months post-surgery, with no significant changes in pain, swelling or scarring 138 
between these two follow-ups. Improvements in redness from 3 (Md=1, range 0-10) to 6 139 
months (Md=0, range 0-10) post-surgery were significant (z=-3.51, p=0.001, r=-0.24). 140 
Psychosocial variables 141 
Statistically significant improvements in psychosocial and functional quality of life, anxiety 142 
and depression, social anxiety and social avoidance, illness and treatment beliefs, fear of 143 
negative evaluation, perceived visibility and, salience and valance of appearance (Table 2) 144 
were found from pre-surgery to 3 months and pre-surgery to 6 months. There were no 145 
significant changes from 3 to 6 months. Overtime the number of participants who were 146 
meeting moderate or ‘caseness’ levels of anxiety or depression, or scoring below normal in 147 
quality of life, reduced significantly from pre-surgery to 6 months post-surgery, whilst the 148 
proportion of patients in the normal classification for mood and above normal in quality of 149 
life increased. There was no statistically significant difference in the proportion of 150 
participants who exceeded the 95% LOAs at 3 and 6 months post-surgery (psychosocial 151 
quality of life: p=0.33; functional quality of life p=0.12). 152 
Relationship between clinical success and quality of life 153 
According to clinical criteria, 110 (52.38%) participants experienced successful surgery, 20 154 
(9.52%) failed and 80 (38.09%) were partial successes. Of these 80 partial successes, 10 155 
(12.5%) were scheduled for further surgery, 43 (53.75%) had been discharged from the 156 
service, 13 (16.25%) had a scheduled follow-up appointment, 9 (11.25%) were receiving 157 
prism therapy and 5 (6.25%) botulinum toxin therapy. Whilst there were no statistically 158 
significant differences between these three groups of patients on changes in functional 159 
quality of life from baseline to 6 months (FR2, 207R= 0.89, p=0.42), there were differences in 160 
11 
changes in psychosocial quality of life (FR2, 207R=4.22, p=0.02, η2=0.04). Post-hoc comparison 161 




Over 80% of patients did not regret having surgery, approximately 6% had some regret 166 
either at 3 or 6 months. Between 70 and 80% of the sample would go through the 167 
operation, only 1-4% would not. 168 
Who benefits most from surgery? 169 
The final model for changes in psychosocial quality of life explained 85% of the total 170 
variance (FR49, 160R= 18.60, p<0.001). The statistically significant predictors were the IPQ-R 171 
consequences subscale, the intimacy and appearance-related issues subscale of the RSSQ, 172 
the DAS24 and perceived visibility at baseline (Table 3). The final model for changes in 173 
functional quality of life explained 72% of the variance (FR49, 160R=8.60, p<0.001). The 174 
statistically significant predictors were ethnicity, classification, the IPQ-R consequences 175 
subscale, the TRI treatment concern subscale, the visual functioning subscale of the ESSQ 176 
and RSSQ, and DAS24 at baseline (Table 3). 177 
Which concepts should be targeted in order to improve the impact of surgery? 178 
The final model for changes in psychosocial quality of life accounted for 78% of the variance 179 
(FR19, 190R=35.78, p<0.001). The statistically significant predictors were changes in; the IPQ-R 180 
consequences subscale, salience, DAS24 and in perceived visibility (Table 4). The final model 181 
for changes in psychosocial quality of life accounted for 51% of the variance (FR19,190R=10.48, 182 
12 
p<0.001). The statistically significant predictors were changes in; the IPQ-R consequences 183 
subscale, perceived visibility, social support from significant others and depression (Table 4). 184 
DISCUSSION 185 
In line with previous research (17;18) strabismus surgery led to significant improvements in 186 
psychosocial and functional quality of life from preoperative assessment through to 3 187 
months post-surgery. No further improvements in quality of life were found at the 6 month 188 
follow-up, supporting previous research (11). Although improvements in psychosocial, but 189 
not functional quality of life, have been found up to 1 year post-surgery (19) this does not 190 
negate the possibility that quality of life curtails 3 months after surgery. Contrary to what 191 
might be expected, improvements in functional quality of life were not associated with how 192 
successful surgery was from a clinical perspective. However, surgery deemed partially 193 
successful was found to be more detrimental, leading to a reduction in psychosocial quality 194 
of life from pre to post-surgery, than either success or failure, which both led to 195 
improvements in psychosocial quality of life. This contradicts other findings, which suggest 196 
no association between success of surgery and changes in psychosocial quality of life, but 197 
small improvements in functional quality of life were in failed surgery and larger 198 
improvements after successful surgery (20). The criteria used to define success and failure 199 
between these studies did however differ and could explain these differences (20).  200 
This study also provides unique evidence that strabismus surgery not only leads to 201 
improvements in quality of life, but other psychosocial domains. The proportion of people 202 
with strabismus living with clinical anxiety or depression is considerably greater than that of 203 
the general population and those with a chronic conditions (1), therefore a reduction in the 204 
number of patients meeting these criteria is an important step towards improving the 205 
13 
mental health of this population. As a result of the restorative nature of strabismus surgery, 206 
it is unsurprising that patients perceived their strabismus as being less visible after surgery 207 
and felt more positive about their appearance, this appears to have enabled participants to 208 
feel more confident and less fearful of interacting and socialising with others, leading to 209 
reductions in social anxiety, and consequently improvements in quality of life.  210 
Greater improvements in quality of life from pre- to post-surgery was more likely in those 211 
who held more positive beliefs about their strabismus and treatment, experienced less 212 
social anxiety and social avoidance and had lower expectations about the outcome of their 213 
surgery prior to surgery. Although one might expect that targeting surgery towards those 214 
who are less able to cope would be more beneficial, these negative beliefs, high 215 
expectations and inability to socialise may impinge on the success of surgery. Being able to 216 
predict who will benefit most from surgery is clearly more complex than targeting those 217 
who appear more severely affected clinically or psychologically. Careful consideration 218 
therefore needs to be taken when listing patients for surgery who report more distress, as 219 
these patients maybe more likely to request further surgery as a result of not meeting high 220 
expectations for example, and may benefit from additional psychosocial support in order to 221 
optimise the benefits of surgery.  222 
This study suggests that quality of life post-surgery could be improved by addressing 223 
people’s beliefs about the negative consequences of their strabismus, challenging the value 224 
they place on appearance and how visible they think their squint is, as well as improving 225 
social skills. The evidence for improving the psychosocial well-being of people with a visible 226 
difference is at present weak, with more theoretically driven interventions, evaluated in 227 
RCTs, required (21). This could involve adapting and tailoring CBT-based or social skills 228 
14 
interventions that have been developed and evaluated in people with a visible difference 229 
(22) for the specific needs of people with strabismus.  230 
The present study is limited by the lack of a randomised control group, which means that 231 
the changes observed from pre- to post-surgery cannot be directly attributed to surgery. 232 
This is however unlikely given the significant psychological impact of living with strabismus, 233 
which is not predicted by disease duration (1).  234 
An appearance that differs from the norm can prove challenging in a society which is 235 
focused on appearance. Restorative surgery, such as ocular realignment, which reduces the 236 
perceived visibility and negative perceptions of one’s own appearance, may therefore 237 
provide a mechanism via which people feel better able to interact and cope in social 238 
situations, and hence reduces fear of negative reactions and social anxiety. It is however 239 
clear that not all experience these benefits despite successful clinical outcomes, therefore 240 
by intervening both psychologically and clinically the findings of this study may provide a 241 
unique mechanism via which the benefits of strabismus surgery can be optimised.  242 
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Titles and legends to figures 305 
Figure 1. Framework outlining the process of psychological adjustment to strabismus 306 



































Disease duration (years) 24 (0-88) 
Age of onset (years) 23 (0-76) 
Previous surgery (yes/no) 98/112 
Total no. of previous strabismus surgeries 1 (0-6) 
Previous Botulinum toxin type A therapy (yes/no) 81/129 
Previous prism therapy for diplopia (yes/no) 47/163 
Worse eye visual acuity - LogMAR Conversionb 0.40 (-0.20 – 2.20) 
Best eye visual acuity - LogMAR Conversionb -0.06 (-0.20 – 0.80) 
Deviation in primary position 
Esotropia 
Exotropia 







Deviation in primary position 33.87 (2-90) 










Below normal threshold 




a Secondary refers to a squint occurring following the loss or impairment of vision. Secondary (iatrogenic) 
refers to squint occurring secondary to sight saving surgery e.g. retinal detachment surgery; b Visual acuity. 
Vision acuity measured as Snellen’s acuity but converter into LogMAR scale for statistical analysis. LogMAR 
values ranged between -0.20 and 2.1. The score of 2.2 LogMAR being assigned to vision of counting fingers, 
hand movements, perception of light and non-perception of light 
 
Table 2. Changes over time, estimated marginal mean (SE) 
   Baseline  3 month  6 month  Statistic  
AS20 Psychosocial  56.45 (1.62)  71.94 (1.75)*  74.65 (1.87)*  F2,273.84 = 82.19,  p < 0.001 
AS20 Function  56.44 (1.44) 68.29 (1.57)* 69.42 (1.67)* F2,280.03 = 53.70,  p < 0.001
Depression  4.69 (0.23)  3.52 (0.25)*  3.21 (0.26)*  F2,286.28 = 24.28,  p < 0.001 
Anxiety  6.94 (0.26) 5.69 (0.28)* 5.79 (0.30)* F2,295.11 = 17.31,  p < 0.001
DAS24   39.29 (0.86)  34.66 (0.93)*  34.46 (0.98)*  F2,242.42 = 24.03,  p < 0.001 
IPQ‐R Personal control  2.51 (0.06) 2.46 (0.06) 2.43 (0.06)  F2,313.36 = 0.72,  p = 0.49
IPQ‐R Consequences  2.99 (0.06)  2.35 (0.07)  2.23 (0.07)  F2,262.84 = 80.64,  p < 0.001 
IPQ‐R Timeline  3.66 (0.07)  3.11 (0.07)  3.04 (0.07)  F2,283.44 = 41.71,  p < 0.001 
TRI Treatment value  2.97 (0.04)  2.86 (0.05)  2.83 (0.05)*  F2,314.04 = 3.99,  p = 0.02 
TRI Treatment Concerns  2.76 (0.05)  2.33 (0.06)*  2.19 (0.06)*  F2,282.80 = 52.12,  p < 0.001 
TRI Decision satisfaction  3.97 (0.04)  4.13 (0.04)*  4.16 (0.04)*  F2,295.88 = 11.86,  p < 0.001 
TRI Cure  3.61 (0.04)  3.27 (0.05)*  3.24 (0.05)*  F2,348.88 = 26.66,  p < 0.001 
FNE  37.11 (0.57)  35.60 (0.61)*  35.52 (0.64)*  F2,272.66 = 7.19, p = 0.01 
Perceived visibility  4.87 (0.12)  3.06 (0.13)*  2.79 (0.14)*  F2,333.02 = 120.55,  p < 0.001 
CARSAL  32.46 (0.42)  30.92 (0.46)*  31.03 (0.48)*  F2,299.58 = 10.51,  p < 0.001 
CARVAL  20.38 (0.49)  17.64 (0.54)*  17.41 (0.57)*  F2,286.99 = 22.65,  p < 0.001 
Social support ‐ Family  16.19 (0.23) 16.10 (0.25) 16.46 (0.26) F2,309.33 = 1.56,  p = 0.21
Social support ‐ Friends  16.00 (0.21)  16.02 (0.23)  16.04 (0.24)  F2,303.20 = 0.02,  p = 0.98 
























































































   β  t  p  95% CI for β 
Lower Bound Upper bound
Outcome: Psychosocial quality of life   
(Constant)  0.00  4.50  0.00  1.70  4.34 
Age  0.00  ‐0.01  0.99  ‐0.01  0.01 
Gender  0.03  0.70  0.48  ‐0.10  0.20 
Ethnicity                
Black  0.02  0.48  0.63  ‐0.28  0.47 
South Asian  ‐0.04  ‐0.98  0.32  ‐0.40  0.13 
Other ethnicity  0.02  0.49  0.62  ‐0.23  0.38 
Classification        
Primary  0.03  0.62  0.54  ‐0.17  0.33 
Residual  0.02  0.41  0.68  ‐0.24  0.37 
Secondary  ‐0.03 ‐0.71 0.48 ‐0.57 0.27
Secondary iatrogenic  0.05  1.18  0.24  ‐0.16  0.63 
Consecutive  0.00 0.00 1.00 ‐0.31 0.31
Mechanical  ‐0.04  ‐0.90  0.37  ‐0.35  0.13 
Other classification  0.01 0.41 0.68 ‐0.46 0.71
Disease duration (years)  ‐0.05  ‐0.61  0.54  ‐0.01  0.01 
Age of onset (years)  ‐0.10 ‐1.24 0.22 ‐0.01 0.00
Previous surgery (yes/no)  ‐0.04  ‐0.61  0.54  ‐0.31  0.16 
Total no. of previous strabismus surgeries  ‐0.03  ‐0.50  0.62  ‐0.13  0.08 
Previous Botulinum toxin type A therapy (yes/no)  0.01  0.24  0.81  ‐0.13  0.17 
Previous prism therapy for diplopia (yes/no)  ‐0.06  ‐1.32  0.19  ‐0.34  0.07 
Worse eye visual acuity ‐ LogMAR Conversion†  ‐0.02  ‐0.43  0.67  ‐0.15  0.10 
Best eye visual acuity ‐ LogMAR Conversion†  0.04  1.14  0.25  ‐0.24  0.91 
   β t p  95% CI for β
Lower Bound  Upper bound 
Deviation in primary position  0.01  0.31  0.75  0.00  0.01 
Deviation in primary position        
Esotropia  ‐0.01  ‐0.17  0.87  ‐0.23  0.19 
Hypertropia or hypotropia  0.01  0.13  0.90  ‐0.25  0.28 
Other direction  0.01  0.26  0.79  ‐0.32  0.43 
Diplopia  0.09  1.65  0.10  ‐0.03  0.38 
IQP‐R Timeline  ‐0.01  ‐0.28  0.78  ‐0.10  0.07 
IQP‐R Consequences  ‐0.18  ‐3.41  0.00  ‐0.32  ‐0.09 
IQP‐R Personal control  ‐0.02  ‐0.51  0.61  ‐0.10  0.06 
TRI Treatment value  0.01 0.30 0.77 ‐0.13 0.17
TRI Treatment concerns  ‐0.03  ‐0.63  0.53  ‐0.13  0.07 
TRI Decision satisfaction  0.00 ‐0.06 0.95 ‐0.18 0.17
TRI Cure  ‐0.02  ‐0.37  0.71  ‐0.19  0.13 
FNE  ‐0.06 ‐1.21 0.23 ‐0.02 0.00
ESSQ Intimacy and appearance‐related issues  ‐0.05  ‐0.73  0.46  ‐0.28  0.13 
ESSQ Visual functioning  0.08 1.17 0.25 ‐0.09 0.36
ESSQ Social functioning  0.02  0.40  0.69  ‐0.23  0.34 
RSSQ Intimacy and appearance‐related issues  ‐0.24  ‐3.57  0.00  ‐0.33  ‐0.09 
RSSQ Visual functioning  0.02  0.36  0.72  ‐0.09  0.13 
RSSQ Social functioning  ‐0.06  ‐1.11  0.27  ‐0.19  0.05 
DAS24  ‐0.25  ‐4.39  0.00  ‐0.03  ‐0.01 
Appearance concern  ‐0.08  ‐1.57  0.12  ‐0.40  0.04 
Perceived visibility   ‐0.26  ‐4.43  0.00  ‐0.19  ‐0.07 
Salience  ‐0.01  ‐0.11  0.91  ‐0.01  0.01 
Valence  0.01 0.15 0.88 ‐0.01 0.01
   β t p  95% CI for β
Lower Bound  Upper bound 
Social support ‐ Family  ‐0.05  ‐1.11  0.27  ‐0.04  0.01 
Social support ‐ Friends  0.04  0.95  0.34  ‐0.01  0.04 
Social support ‐ Significant others  0.05  1.20  0.23  ‐0.01  0.03 
Anxiety  ‐0.03  ‐0.60  0.55  ‐0.03  0.02 
Depression  ‐0.01  ‐0.10  0.92  ‐0.03  0.03 
           
Outcome: Functional quality of life           
(Constant)  0.00  4.66  0.00  2.35  5.76 
Age  ‐0.01  ‐0.12  0.91  ‐0.01  0.01 
Gender  0.05 0.91 0.36 ‐0.11 0.29
Ethnicity                
Black  0.05 0.97 0.33 ‐0.23 0.69
South Asian  0.06  1.12  0.26  ‐0.16  0.57 
Other ethnicity  0.10 2.12 0.03 0.03 0.83
Classification        
Primary  ‐0.05 ‐0.73 0.47 ‐0.45 0.21
Residual  ‐0.01  ‐0.18  0.86  ‐0.44  0.36 
Secondary  0.00  0.00  1.00  ‐0.56  0.56 
Secondary iatrogenic  ‐0.14  ‐2.62  0.01  ‐1.22  ‐0.17 
Consecutive  0.08  0.92  0.36  ‐0.22  0.61 
Mechanical  ‐0.10  ‐1.58  0.11  ‐0.58  0.06 
Other classification  ‐0.06  ‐1.25  0.21  ‐1.25  0.28 
Disease duration (years)  ‐0.10  ‐0.96  0.34  ‐0.01  0.01 
Age of onset (years)  ‐0.09  ‐0.79  0.43  ‐0.01  0.01 
Previous surgery (yes/no)  ‐0.11 ‐1.34 0.18 ‐0.52 0.10
   β t p  95% CI for β
Lower Bound  Upper bound 
Total no. of previous strabismus surgeries  0.07  0.83  0.41  ‐0.08  0.19 
Previous Botulinum toxin type A therapy (yes/no)  0.09  1.76  0.08  ‐0.02  0.38 
Previous prism therapy for diplopia (yes/no)  0.08  1.41  0.16  ‐0.08  0.46 
Worse eye visual acuity ‐ LogMAR Conversion†  0.05  0.78  0.44  ‐0.10  0.23 
Best eye visual acuity ‐ LogMAR Conversion†  0.01  0.28  0.78  ‐0.65  0.86 
Deviation in primary position  0.01  0.10  0.92  ‐0.01  0.01 
Deviation in the primary position        
Esotropia  0.00  0.05  0.96  ‐0.27  0.29 
Hypertropia or hypotropia  0.15  1.85  0.07  ‐0.02  0.68 
Other direction  0.06 1.03 0.30 ‐0.23 0.75
Diplopia  ‐0.10  ‐1.46  0.14  ‐0.48  0.07 
IQP‐R Timeline  ‐0.01 ‐0.21 0.83 ‐0.12 0.10
IQP‐R Consequences  ‐0.28  ‐3.81  0.00  ‐0.45  ‐0.14 
IQP‐R Personal control  0.04 0.88 0.38 ‐0.06 0.16
TRI Treatment value  ‐0.03  ‐0.52  0.60  ‐0.25  0.15 
TRI Treatment concerns  ‐0.15 ‐2.49 0.01 ‐0.30 ‐0.04
TRI Decision satisfaction  ‐0.05  ‐0.78  0.44  ‐0.31  0.14 
TRI Cure  ‐0.02  ‐0.26  0.80  ‐0.24  0.18 
FNE  ‐0.06  ‐0.85  0.39  ‐0.02  0.01 
ESSQ Intimacy and appearance‐related issues  0.15  1.68  0.10  ‐0.04  0.51 
ESSQ Visual functioning  ‐0.17  ‐2.04  0.04  ‐0.54  ‐0.01 
ESSQ Social functioning  ‐0.02  ‐0.31  0.76  ‐0.43  0.31 
RSSQ Intimacy and appearance‐related issues  0.11  1.26  0.21  ‐0.05  0.25 
RSSQ Visual functioning  ‐0.20  ‐2.42  0.02  ‐0.33  ‐0.03 
RSSQ Social functioning  0.00 ‐0.06 0.96 ‐0.16 0.15
   β t p  95% CI for β
Lower Bound  Upper bound 
DAS24  ‐0.21  ‐2.78  0.01  ‐0.03  0.00 
Appearance concern  0.00  0.01  0.99  ‐0.29  0.29 
Perceived visibility  0.05  0.60  0.55  ‐0.05  0.10 
Salience  ‐0.07  ‐1.09  0.27  ‐0.03  0.01 
Valence  0.00  ‐0.06  0.95  ‐0.02  0.02 
Social support ‐ Family  ‐0.06  ‐0.85  0.40  ‐0.05  0.02 
Social support ‐ Friends  0.05  0.72  0.47  ‐0.02  0.05 
Social support ‐ Significant others  ‐0.08  ‐1.32  0.19  ‐0.04  0.01 
Anxiety  ‐0.06  ‐0.92  0.36  ‐0.04  0.02 
Depression  ‐0.14 ‐1.94 0.05 ‐0.07 0.00
 
Table 4. Changes in clinical and psychosocial variables that predict change in psychosocial and functional quality of life 
   β  t  p  95% CI for β 
Lower Bound  Upper Bound 
Outcome: Psychosocial quality of life           
(Constant)  0.00  0.39  0.69  ‐0.08  0.12 
Success           
Partial success  ‐0.03  ‐0.78  0.44  ‐0.22  0.09 
Unsuccessful  0.00  ‐0.13  0.90  ‐0.27  0.24 
Change in IPQ‐R Timeline  0.00  0.04  0.97  ‐0.08  0.08 
Change in IPQ‐R Consequences  ‐0.16  ‐3.09  0.00  ‐0.26  ‐0.06 
Change in IPQ‐R Personal control  ‐0.01  ‐0.15  0.88  ‐0.08  0.07 
Change in TRI Treatment value  0.02  0.48  0.63  ‐0.07  0.12 
Change in TRI Treatment concerns  ‐0.03  ‐0.78  0.43  ‐0.11  0.05 
Change in TRI Decision satisfaction  ‐0.02  ‐0.40  0.69  ‐0.10  0.07 
Change in TRI Cure  ‐0.04  ‐0.77  0.44  ‐0.14  0.06 
Change in FNE  ‐0.04  ‐0.85  0.39  ‐0.14  0.06 
Change in Salience  ‐0.11  ‐2.33  0.02  ‐0.20  ‐0.02 
Change in DAS24  ‐0.31  ‐5.42  0.00  ‐0.41  ‐0.19 
Change in Valence  ‐0.05  ‐0.93  0.35  ‐0.14  0.05 
Change in Perceived visibility  ‐0.42  ‐8.68  0.00  ‐0.51  ‐0.32 
Change in Social support ‐ Significant others  0.07  1.53  0.13  ‐0.02  0.16 
Change in Social support ‐ Family  ‐0.06  ‐1.20  0.23  ‐0.16  0.04 
Change in Social support ‐ Friends  0.02  0.38  0.70  ‐0.07  0.11 
Change in Anxiety  ‐0.06  ‐1.13  0.26  ‐0.16  0.04 
Change in Depression  0.04  0.73  0.47  ‐0.07  0.14 
           
Outcome: Functional quality of life           
(Constant)  0.00  ‐0.36  0.72  ‐0.17  0.12 
Success                
Partial success  0.01  0.22  0.83  ‐0.21  0.26 
Unsuccessful  0.00  0.01  0.99  ‐0.36  0.36 
Change in IPQ‐R Timeline  0.01  0.15  0.88  ‐0.11  0.13 
Change in IPQ‐R Consequences  ‐0.38  ‐4.83  0.00  ‐0.51  ‐0.22 
Change in IPQ‐R Personal control  0.06  1.06  0.29  ‐0.05  0.16 
Change in TRI Treatment value  ‐0.09  ‐1.20  0.23  ‐0.22  0.05 
Change in TRI Treatment concerns  ‐0.12  ‐1.97  0.05  ‐0.24  0.00 
Change in TRI Decision satisfaction  ‐0.06  ‐0.94  0.35  ‐0.19  0.07 
Change in TRI Cure  0.05  0.64  0.52  ‐0.10  0.19 
Change in FNE  0.02  0.29  0.77  ‐0.12  0.16 
Change in DAS24  ‐0.07  ‐0.82  0.41  ‐0.22  0.09 
Change in Salience  0.01  0.08  0.94  ‐0.13  0.14 
Change in Valence  ‐0.02  ‐0.26  0.79  ‐0.16  0.12 
Change in Perceived visibility  0.23  3.28  0.00  0.09  0.36 
Change in Social support ‐ Significant others  ‐0.13  ‐2.07  0.04  ‐0.26  ‐0.01 
Change in Social support ‐ Family  ‐0.02  ‐0.29  0.77  ‐0.16  0.12 
Change in Social support ‐ Friends  0.09  1.30  0.19  ‐0.04  0.22 
Change in Anxiety  ‐0.05  ‐0.60  0.55  ‐0.19  0.10 
Change in Depression  ‐0.34  ‐4.39  0.00  ‐0.49  ‐0.19 
 
